DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

BACKGROUND: RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouphael, Nadine G., Morgan, Cecilia, Li, Shuying S., Jensen, Ryan, Sanchez, Brittany, Karuna, Shelly, Swann, Edith, Sobieszczyk, Magdalena E., Frank, Ian, Wilson, Gregory J., Tieu, Hong-Van, Maenza, Janine, Norwood, Aliza, Kobie, James, Sinangil, Faruk, Pantaleo, Giuseppe, Ding, Song, McElrath, M. Juliana, De Rosa, Stephen C., Montefiori, David C., Ferrari, Guido, Tomaras, Georgia D., Keefer, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2019
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819112/
https://www.ncbi.nlm.nih.gov/pubmed/31566579
http://dx.doi.org/10.1172/JCI128699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819112/
https://www.ncbi.nlm.nih.gov/pubmed/31566579
http://dx.doi.org/10.1172/JCI128699

Ejemplares similares